Esperion Therapeutics, Inc. (ESPR) announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C (bad cholesterol) and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the ...

I maintain my buy rating on Esperion Therapeutics, Inc.(NASDAQ: ESPR ) given its strong Q3 2024 financial performance, which is a testament to the success of its unique value proposition discussed in my previousI am an experienced financial analyst and a former writer for Fade The Market on Seeking Alpha, with a passion for numbers and a knack for unraveling complex financial data. Armed with a strong financial modeling and data analysis background, I thrive on providing accurate insights and recommendation ...

Esperion Therapeutics, Inc. (ESPR) incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of $55 million.Shares of Esperion ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.15 per share when it actually produced a loss of $0.05, delivering a surprise of 66.67%.Over the last four quarters, ...

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Esper ...

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Es ...

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media sec ...

Company Overview - Esperion is focused on discovering, developing, and commercializing innovative medicines aimed at improving outcomes for patients with cardiovascular and cardiometabolic diseases [4] - The company addresses the unmet health needs of millions suffering from high cholesterol, emphasizing the importance of reducing LDL-cholesterol levels effectively [4] Equity Incentive Plan - On September 23, 2024, Esperion granted 3,500 restricted stock units (RSUs) to a new employee under its 2017 Inducement Equity Incentive Plan [1] - The 2017 Inducement Equity Incentive Plan is designed for granting equity awards to individuals who are new hires or returning after a bona fide period of non-employment, as an inducement for joining the company [2] RSU Vesting Schedule - Each RSU will vest 25% on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on the employee's continued employment [3]

It has been about a month since the last earnings report for Esperion Therapeutics (ESPR) . Shares have lost about 3.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Esperion's Q2 Loss Narrow ...

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – – Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers – – NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Bo ...